MONTVERDE, FL – November 6, 2025 – GalenusRx is proud to partner with Hesperos Inc. through a prestigious Small Business Innovative Research (SBIR) grant awarded by the National Institute on Aging, part of The National Institutes of Health.
This grant highlights our shared commitment to advancing predictive models that address the growing concern of anticholinergic drug-induced dementia in aging populations. Further, this award represents a major milestone in our mission to revolutionize how we predict and prevent drug-induced neurodegeneration. By combining Hesperos’ expertise in bioengineering with GalenusRx’s strengths in computational pharmacology, we aim to deliver transformative solutions.
As part of our ongoing dedication to improving drug safety for older adults, GalenusRx is developing tools to support clinicians in making safer prescribing decisions. On behalf of GalenusRx, Dr. Jacques Turgeon and Dr. Veronique Michaud are honored to contribute to this important research initiative, which prioritizes the health and well-being of aging individuals.